Applied Filters
Oxford Nanopore signs CRISPR licence
UK-based Oxford Nanopore has obtained a licence to CRISPR-Cas9 IP for nanopore sequencing, a third-generation approach used in the sequencing of biopolymers.
AG advises CJEU on rights of plant variety owners
Advocate general Henrik Saugmandsgaard Øe has advised Europe’s highest court on the scope of protection held by owners of plant variety rights.
CJEU hands down Bayer damages decision
The Court of Justice of the European Union last week issued its decision in a case concerning whether a ‘launch at risk’ bars compensation for a wrongfully issued preliminary injunction.
UK govt invests in ‘world's largest’ genetics research project
The world's ”largest genetics project” to tackle deadly diseases was launched yesterday, September 11, supported by funding from the UK government, charities and four pharmaceutical companies.
Novartis and BenevolentAI sign AI oncology deal
Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.
Lupin and Boehringer enter $720m anti-cancer drug partnership
Indian drugmaker Lupin and German pharma company Boehringer Ingelheim have formed an alliance to develop a therapy for patients with difficult-to-treat cancers.
No-deal Brexit could ‘irreparably’ harm NHS and delay drugs: BMA
Leaving the EU without a deal in place could “irreparably” harm the UK’s National Health Service and lead to delays in new products being bought to market in the country, according to the British Medical Association.
Pinsent Masons hires Fieldfisher’s co-head of life sciences
Nicole Jadeja, the former co-head of life sciences at Fieldfisher, has joined Pinsent Masons as a partner in its London office.
UK faces medicine shortages after no deal: leaked govt report
A leaked UK government report reveals that a no deal Brexit may result in shortages of medicines and other pharmaceutical products.
Bayer to sell off animal health business for $7.6bn
Bayer has agreed to sell its animal health business to US-based Elanco Animal Health for $7.6 billion, as part of its strategic plan to focus on its core life sciences businesses.
